Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic vs Classic XELOX in mCRC
NCT04425564Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2016
- Primary completion
- Jun 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Started Jan 2016; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04425564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425564.